International Capital Strength Portfolio, Series 64
Ticker Symbol: FYATZX
30 Holdings (As of Day of Deposit) |
Ticker |
Company Name |
Initial
Weight |
Price* |
Canada (3.33%) |
CNQ |
Canadian Natural Resources Limited |
3.33% |
$34.40 |
Denmark (3.30%) |
NVO |
Novo Nordisk A/S |
3.30% |
128.17 |
France (3.34%) |
TTE |
TotalEnergies SE |
3.34% |
66.76 |
Germany (6.65%) |
DBOEY |
Deutsche Boerse AG |
3.33% |
19.96 |
IFNNY |
Infineon Technologies AG |
3.32% |
33.17 |
Ireland (13.34%) |
ACN |
Accenture Plc |
3.35% |
315.88 |
CRH |
CRH Plc |
3.33% |
81.54 |
EXPGY |
Experian Plc |
3.31% |
44.57 |
PDD |
PDD Holdings Inc. |
3.35% |
138.02 |
Japan (3.35%) |
TOELY |
Tokyo Electron Limited |
3.35% |
98.30 |
The Netherlands (6.66%) |
ASML |
ASML Holding N.V. |
3.32% |
876.65 |
NXPI |
NXP Semiconductors N.V. |
3.34% |
245.24 |
Singapore (3.34%) |
DBSDY |
DBS Group Holdings Ltd. |
3.34% |
102.41 |
Spain (3.32%) |
IDEXY |
Industria de Diseno Textil, S.A. |
3.32% |
23.72 |
Sweden (9.97%) |
ATLKY |
Atlas Copco AB |
3.32% |
16.95 |
SPOT |
Spotify Technology S.A. |
3.33% |
338.32 |
VLVLY |
Volvo AB |
3.32% |
24.36 |
Switzerland (19.99%) |
ABBNY |
ABB Ltd |
3.33% |
52.31 |
CB |
Chubb Limited |
3.26% |
269.22 |
NSRGY |
Nestle S.A. |
3.35% |
102.89 |
NVS |
Novartis AG |
3.36% |
111.02 |
RHHBY |
Roche Holding AG |
3.32% |
39.83 |
TEL |
TE Connectivity Ltd. |
3.37% |
143.46 |
Taiwan (3.36%) |
TSM |
Taiwan Semiconductor Manufacturing Company Ltd. |
3.36% |
164.55 |
United Kingdom (20.05%) |
AZN |
AstraZeneca Plc |
3.35% |
81.85 |
BAESY |
BAE Systems Plc |
3.34% |
65.75 |
GSK |
GSK Plc |
3.33% |
40.02 |
LIN |
Linde Plc |
3.39% |
447.54 |
RIO |
Rio Tinto Plc |
3.34% |
62.92 |
UL |
Unilever Plc |
3.30% |
61.42 |
*As of the close of business on 8/8/24.
Market values are for reference only and are not indicative of your individual
cost basis.
Not FDIC Insured Not Bank Guaranteed May Lose Value |
Portfolio Summary |
Initial Date of Deposit |
8/9/2024 |
Initial Public Offering Price |
$10.00 per Unit |
Portfolio Ending Date |
8/10/2026 |
Cash CUSIP |
30337G402 |
Reinvestment CUSIP |
30337G410 |
Fee Account Cash CUSIP |
30337G428 |
Fee Account Reinvestment CUSIP |
30337G436 |
Portfolio Statistics* |
Median Market Capitalization: |
$102.1 Billion |
Median Long-Term Debt/Market Value of Equity: |
10.38% |
Median Return on Equity: |
25.94% |
*Capital IQ, as of the close of business on 8/2/24. These median portfolio statistics were determined at a
particular point in time. These statistics will fluctuate over the life of the trust, potentially negatively. Longterm
debt/market value of equity measures the amount of a company’s financial leverage. Return on equity
measures how much profit a company generates on its shareholders’ equity. There is no guarantee these
valuation measures will benefit the securities selected for the trust.
Fee Table (based on a $10 public offering
price per unit) |
|
Standard |
Fee/Wrap |
Deferred Sales Charge |
2.25% |
— |
Creation & Development Fee (C&D Fee) |
0.50% |
0.50% |
Maximum Sales Charge |
2.75% |
0.50% |
|
|
|
Estimated Organization Costs |
0.230% |
0.230% |
Estimated Annual Trust Operating Expenses |
0.218% |
0.218% |
The deferred sales charge will be deducted in three monthly installments commencing 11/20/24. When
the public offering price is less than or equal to $10.00 per unit, there will be no initial sales charge. If the
price exceeds $10.00 per unit, you will pay an initial sales charge. The C&D fee is a charge of $0.050 per unit
collected at the end of the initial offering period. If the price you pay exceeds $10.00 per unit, the C&D fee
will be less than 0.50%; if the price you pay is less than $10.00 per unit, the C&D fee will exceed 0.50%.
Estimated organization costs will be deducted from the assets of the trust at the end of the initial offering
period. Estimated organization costs and trust operating expenses are assessed on a fixed dollar amount per
unit basis which, as a percentage of average net assets, will vary over time. Actual expenses may be more or
less than the estimates. Please see “Fee Table” in the trust prospectus for additional information.
You should consider the portfolio's investment objectives, risks, and
charges and expenses carefully before investing. Contact your financial professional
or call First Trust Portfolios, L.P. at 1.800.621.1675 to request a prospectus,
which contains this and other information about the portfolio. Read it carefully
before you invest.
Risk Considerations
An investment in this unmanaged unit investment trust should be made with an understanding of the risks involved with owning common stocks, such as an economic recession and the
possible deterioration of either the financial condition of the issuers of the equity securities or the general condition of the stock market.
A significant percentage of the securities held by the trust are issued by companies headquartered or incorporated in Europe and therefore the portfolio may present more risks than a portfolio which is broadly diversified over
several regions.
Securities of non-U.S. issuers are subject to additional risks, including currency fluctuations, political risks, withholding, the lack of adequate financial information, and exchange control restrictions impacting non-U.S. issuers.
Large capitalization companies may grow at a slower rate than the overall market.
As the use of Internet technology has become more prevalent in
the course of business, the trust has become more susceptible to
potential operational risks through breaches in cybersecurity.
Ongoing armed conflicts between Russia and Ukraine in Europe and among Israel, Hamas and other militant
groups in the Middle East, have caused and could continue to cause significant market disruptions and volatility
within the markets in Russia, Europe, the Middle East and the United States. The hostilities and sanctions
resulting from those hostilities could have a significant impact on certain investments as well as performance.
The ongoing effects of the COVID-19 global pandemic, or the potential impacts of any future public health crisis, may cause significant volatility and uncertainty in global financial markets. While vaccines have been developed,
there is no guarantee that vaccines will be effective against future variants of the disease.
The value of the securities held by the trust may be subject to steep
declines or increased volatility due to changes in performance or
perception of the issuers.
This UIT is a buy and hold strategy and investors should consider
their ability to hold the trust until maturity. There may be tax
consequences unless units are purchased in an IRA or other
qualified plan.